NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Motilal Oswal Maintains Neutral Rating for Alkyl Amines Chemicals

Alkyl Amines Chemicals (AACL) has reported a steady operating performance with a 4% year-over-year (YoY) increase in earnings before interest, taxes, depreciation, and amortization (EBITDA) in 4QFY26. The company's ability to mitigate raw material cost pressures through price pass-throughs has resulted in a 70 basis points (bp) YoY improvement in EBITDA margin to 18.3%. Despite flat volume growth in FY26, the management expects a steady improvement in growth momentum, driven by rising demand from the pharma segment led by peptides, with a guided overall volume growth of 5-10%.

AACL's prospects are further strengthened by the anti-dumping duty (ADD) on acetonitrile, which is likely to aid price recovery and enhance the company's market position. Our research suggests that the company's operating performance will continue to improve, driven by the expected growth in demand from the pharma segment.

Key Estimates and Projections

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

MetricFY26FY27FY28
Revenue Growth-6%6%
EBITDA Growth4%7%7%
PAT Growth-9%9%

We maintain our earnings estimates and value the stock at 40x FY28E earnings per share (EPS) to arrive at our target price of INR1,720. Based on our analysis, we reiterate our Neutral rating for Alkyl Amines Chemicals.

Investor Takeaway

Maintain Neutral rating with a target price of Rs 1720.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.